2.1. Design and Participants
Paget’s disease, obesity, gout, knee pain
RHEUMATOID ARTHRITIS, OBESITY, CHRONIC INFLAMMATORY DISEASE, TERMINAL ILLNESS, GOUT, CHRONIC PAIN SYNDROME
This was a single-center, randomized, double-blind, and controlled study with four arms carried out at the Health Sciences Department of Universidad Católica San Antonio de Murcia (UCAM), in Murcia, Spain. The study period was from 26 January to 18 November 2022. The primary objective of the study was to assess the efficacy of a combination product containing omega-3 fatty acids as well as Participants were mainly recruited by advertising the study through mass media and social networks available at UCAM University. Eligibility included subjects of both sexes in an age range of 40 to 75 years with persistent unilateral knee pain (> 3 using a 1–10 cm visual analog scale (VAS)). When knee pain was bilateral, the knee with the highest VAS score was chosen. Exclusion criteria were as follows: previous use of OA medications such as NSAIDs, opiates, or immunosuppressants; current treatment with chondroitin sulfate, glucosamine, or hyaluronic acid intra-articular injections; use of any supplement for improving health joints; chronic inflammatory diseases of the musculoskeletal system (such as gout, rheumatoid arthritis, Paget’s disease, chronic pain syndrome, etc.); severe or terminal illness; obesity (body mass index (BMI) > 32 kg/mThe study protocol was approved by the Ethics Committee of Universidad Católica San Antonio de Murcia (code CE062105; approval date 25 June 2021) (Murcia, Spain) and was registered in the 